115563
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
一项关于肝动脉灌注化疗联合酪氨酸激酶抑制剂和 PD-1 抑制剂治疗合并主门静脉癌栓（VP4）的肝细胞癌患者的回顾性研究
Authors Wang X , Chen S , Yu W, Liu W, Fang Z
Received 27 September 2025
Accepted for publication 14 December 2025
Published 7 January 2026 Volume 2026:13 562766
DOI https://doi.org/10.2147/JHC.S562766
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Editor who approved publication: Dr Mohamed Shaker
Xiaolong Wang, Shiguang Chen, Wenchang Yu, Weifu Liu, Zhuting Fang
Department of Oncology and Vascular Interventional Therapy, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, 350014, People’s Republic of China
Correspondence: Zhuting Fang, Department of Oncology and Vascular Interventional Therapy,Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, 350014, People’s Republic of China, Email ztfang@fjzlhospital.com
Background: Patients with hepatocellular carcinoma (HCC) involving main portal vein tumor thrombosis (Vp4) face a dismal prognosis with limited treatment options. While combination therapy comprising hepatic arterial infusion chemotherapy (HAIC), tyrosine kinase inhibitors (TKIs), and PD-1 inhibitors has emerged as a potential strategy, real-world clinical data regarding its efficacy and safety in this subset of patients remain scarce.
Methods: This retrospective study enrolled 35 Vp4 HCC patients who received HAIC combine with TKI and PD-1 inhibitor. Treatment response was evaluated according to mRECIST and RECIST1.1. Survival outcomes including progression-free survival (PFS) and overall survival (OS) were analyzed using the Kaplan–Meier method, and independent prognostic factors were identified via Cox regression analyses.
Results: Of 35 patients (mean age 52.7 ± 8.3 years, 97.1% male, 97.1% HBV-infected), 37.1% had extrahepatic metastasis and 57.1% had ≥ 4 tumors. After a median follow-up of 313 days (IQR, 177.5– 464.5), the objective response rate (ORR) by mRECIST was 60.0%. Median OS and PFS were 313 days (95% CI: 257.5– 368.5) and 204 days (95% CI: 153.9– 254.1) respectively. Hepatic vein tumor thrombus/inferior vena cava tumor thrombus (HVTT/IVCTT) independently predicted worse PFS (HR = 2.860, p = 0.023) and OS (HR = 3.482, p = 0.007), and tumor number ≥ 4 predicted inferior OS (HR = 2.454, p = 0.020). Grade 3– 4 AEs occurred in 45.7% of patients, most commonly elevated AST (34.3%), with no grade 5 events.
Conclusion: The combination of HAIC, TKI, and PD-1 inhibitor demonstrates encouraging antitumor activity and a manageable safety profile in patients with Vp4 HCC, indicating its potential as an effective treatment option for this clinically challenging population.
Keywords: hepatocellular carcinoma, hepatic arterial infusion chemotherapy, portal vein
Department of Oncology and Vascular Interventional Therapy, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, 350014, People’s Republic of China
Correspondence: Zhuting Fang, Department of Oncology and Vascular Interventional Therapy,Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, 350014, People’s Republic of China, Email ztfang@fjzlhospital.com
Background: Patients with hepatocellular carcinoma (HCC) involving main portal vein tumor thrombosis (Vp4) face a dismal prognosis with limited treatment options. While combination therapy comprising hepatic arterial infusion chemotherapy (HAIC), tyrosine kinase inhibitors (TKIs), and PD-1 inhibitors has emerged as a potential strategy, real-world clinical data regarding its efficacy and safety in this subset of patients remain scarce.
Methods: This retrospective study enrolled 35 Vp4 HCC patients who received HAIC combine with TKI and PD-1 inhibitor. Treatment response was evaluated according to mRECIST and RECIST1.1. Survival outcomes including progression-free survival (PFS) and overall survival (OS) were analyzed using the Kaplan–Meier method, and independent prognostic factors were identified via Cox regression analyses.
Results: Of 35 patients (mean age 52.7 ± 8.3 years, 97.1% male, 97.1% HBV-infected), 37.1% had extrahepatic metastasis and 57.1% had ≥ 4 tumors. After a median follow-up of 313 days (IQR, 177.5– 464.5), the objective response rate (ORR) by mRECIST was 60.0%. Median OS and PFS were 313 days (95% CI: 257.5– 368.5) and 204 days (95% CI: 153.9– 254.1) respectively. Hepatic vein tumor thrombus/inferior vena cava tumor thrombus (HVTT/IVCTT) independently predicted worse PFS (HR = 2.860, p = 0.023) and OS (HR = 3.482, p = 0.007), and tumor number ≥ 4 predicted inferior OS (HR = 2.454, p = 0.020). Grade 3– 4 AEs occurred in 45.7% of patients, most commonly elevated AST (34.3%), with no grade 5 events.
Conclusion: The combination of HAIC, TKI, and PD-1 inhibitor demonstrates encouraging antitumor activity and a manageable safety profile in patients with Vp4 HCC, indicating its potential as an effective treatment option for this clinically challenging population.
Keywords: hepatocellular carcinoma, hepatic arterial infusion chemotherapy, portal vein